HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY

HEP DART 2021：肝病药物开发前沿

• 批准号: 10391910
• 负责人: Raymond Felix Schinazi
• 金额: $ 1.2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-04 至 2022-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391910
• 关键词: Accreditation; Address; Adolescent; Advocate; Applications Grants; Area; Atmosphere; Award; Biology; COVID-19; COVID-19 pandemic; Categories; Chemistry; Clinical; Clinical Research; Combined Modality Therapy; Communities; Development; Disease; Disease Outcome; Doctor of Philosophy; Educational workshop; Ensure; Epidemiology; Event; Faculty; Fibrosis; Flare; Future; Grant; Guidelines; HIV; Health Personnel; Health Professional; Hepatitis; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatology; Immunity; Immunotherapy; Infection; International; Knowledge; Learning; Liver diseases; Malignant Neoplasms; Medical; Minority; Nurses; Oral; Pediatrics; Persons; Pharmacology; Physician Assistants; Physicians; Population; Postdoctoral Fellow; Primary carcinoma of the liver cells; Process; Public Health; Regimen; Research Personnel; Role; Scholarship; Scientist; Stream; Therapeutic; Training; Travel; Treatment Protocols; Treatment outcome; United States National Institutes of Health; Universities; Vaccination; Vaccines; Viral Pathogenesis; Viral hepatitis; Virus; Virus Diseases; Woman; Work; chronic liver disease; clinical development; co-infection; continuing medical education; cost; drug development; frontier; graduate student; improved; interest; liver infection; meetings; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel marker; posters; prevent; programs; symposium; therapeutic development; therapeutic vaccine; therapy development; vaccine development; vaccinology; virtual; Accreditation; Address; Adolescent; Advocate; Applications Grants; Area; Atmosphere; Award; Biology; COVID-19; COVID-19 pandemic; Categories; Chemistry; Clinical; Clinical Research; Combined Modality Therapy; Communities; Development; Disease; Disease Outcome; Doctor of Philosophy; Educational workshop; Ensure; Epidemiology; Event; Faculty; Fibrosis; Flare; Future; Grant; Guidelines; HIV; Health Personnel; Health Professional; Hepatitis; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatology; Immunity; Immunotherapy; Infection; International; Knowledge; Learning; Liver diseases; Malignant Neoplasms; Medical; Minority; Nurses; Oral; Pediatrics; Persons; Pharmacology; Physician Assistants; Physicians; Population; Postdoctoral Fellow; Primary carcinoma of the liver cells; Process; Public Health; Regimen; Research Personnel; Role; Scholarship; Scientist; Stream; Therapeutic; Training; Travel; Treatment Protocols; Treatment outcome; United States National Institutes of Health; Universities; Vaccination; Vaccines; Viral Pathogenesis; Viral hepatitis; Virus; Virus Diseases; Woman; Work; chronic liver disease; clinical development; co-infection; continuing medical education; cost; drug development; frontier; graduate student; improved; interest; liver infection; meetings; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel marker; posters; prevent; programs; symposium; therapeutic development; therapeutic vaccine; therapy development; vaccine development; vaccinology; virtual

Abstract/ Project summary: HEP DART 2021: Frontiers in Drug Development for Hepatology HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference attracting at least 250 attendees per meeting for the past 24 years. HEP DART is open to anyone interested in therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to interest primarily scientists and clinical researchers with a focus on drug development and vaccinology. The aim of HEP DART 2021 is to assemble clinicians, researchers, basic scientists, nurses, physician assistants and advocates together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for liver infection, disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis such as HBV, HCV, and HDV. (2) Evaluate the progress toward the elimination of HBV and HCV as public health threats in the context of the COVID-19 pandemic. (3) Describe the latest developments in HBV curative strategies, including combination therapy for cure. (4) Highlight the latest findings in immunity, flares, immunotherapy and cure strategies. (5) Highlight advances in drug development against NASH, NAFLD, fibrosis and HCC. (6) Describe novel biomarkers for viral hepatitis, liver disease, and treatment outcomes. (7) Review the latest findings related to COVID-19 and liver disease. (8) Review current treatment and vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (9) Examine recent work and future directions for vaccines to prevent HCV infection. (10) Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (11) Assess the role of therapeutic vaccines in future therapies for viral hepatitis, NASH, and co-infections with HIV. (12) Understand the epidemiology and pathogenesis of viral hepatitis including HBV-HDV, HCV, HAV and HEV. (13) Understand treatment in the context of co-infection with HIV and other viruses. METHODS: HEP DART 2021 comprises four days of in- person scientific presentations, delivered in both oral and poster presentations formats via non-concurrent sessions. Main sessions and keynote speakers will also be taped and streamed virtually shortly after the meeting. Emory University, Office of Continuing Medical Education will designate category 1 credits toward the AMA Physician’s Recognition Award to this accredited program. HEP DART provides a relaxed and scientifically stimulating atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray costs of scholarships and travel grants for young investigators, women, visible minorities and other under- represented delegates.

摘要/项目摘要：HEP DART 2021：肝病药物开发前沿 HEP DART：肝病学药物开发前沿是一次独立的双年展会议，吸引了 在过去24年中，每次会议中至少有250名参与者。 Hep Dart向对疗法感兴趣的任何人开放 病毒肝炎和慢性肝病。这次会议的内容是引起了初选的兴趣 专注于药物开发和疫苗学的科学家和临床研究人员。 Hep Dart的目的 2021将组装临床医生，研究人员，基础科学家，护士，身体助理和倡导者 共同提高我们对正在进行的药物开发过程的了解 （HBV，HCV，HDV，HAV和HEV），非酒精性脂肪性肝炎（NASH）和肝细胞癌（HCC）。 Hep Dart将独特地融合生物学，化学，药理学和临床研究的领域，以提供 科学界对治疗中当前和未来的挑战有了越来越多的了解 肝感染，疾病和癌症。目标：（1）突出显示针对病毒的药物开发进步 HBV，HCV和HDV等肝炎。 （2）评估消除HBV和HCV的进度 公共卫生威胁在19009年大流行的背景下。 （3）描述HBV中的最新发展 治疗策略，包括治疗联合疗法。 （4）强调免疫，耀斑的最新发现， 免疫疗法和治愈策略。 （5）突出显示针对NASH，NAFLD，纤维化的药物开发进步 和HCC。 （6）描述病毒肝炎，肝病和治疗结果的新型生物标志物。 （7）评论 与Covid-19和肝病有关的最新发现。 （8）审查当前治疗和疫苗接种 病毒肝炎指南；描述改进治疗方案的进步。 （9）检查最近的工作 以及疫苗预防HCV感染的未来方向。 （10）了解HBV感染的后果 和纳什（Nash）在儿科和青少年人群中。 （11）评估将来治疗疫苗的作用 病毒性肝炎，NASH和HIV共同感染的疗法。 （12）了解流行病学和 病毒肝炎的发病机制，包括HBV-HDV，HCV，HAV和HEV。 （13）了解治疗 与艾滋病毒和其他病毒共同感染的背景。方法：HEP DART 2021包括四天的IN- 人体科学演示，以非符号的口头和海报演示格式交付 会议。会议结束后，几乎不久，主要会议和主题演讲者也将被录制和流式传输。 埃默里大学（Emory University），继续医学教育办公室将指定AMA的1类学分 该认可计划的医师认可奖。 Hep Dart提供了放松和科学的放松 刺激博士学位和MD的氛围，以共同学习和学习。请求支持以帮助 年轻调查人员，妇女，可见少数民族和其他不足的奖学金和旅行补助金的费用 代表代表。